Slide 1: BB-301 Interim Clinical Study Results for Subject 1
BB-301 Interim Clinical Study Results for Subject 1: Previously Announced 90-Day Post-Dose Interim Clinical Study Results At the 90-day post-dose assessment following the administration of the low-dose of BB-301, Subject 1 demonstrated improvements in key VFSS assessments which correlated with the o
Slide 2: Thin Liquid (6 mL), Total Pharyngeal Residue %
Thin Liquid (6 mL), Total Pharyngeal Residue % Pre-Dose Avg. TPR: 4.9% Post-Dose Avg. TPR: 2.8% Lowest TPR-NH: 2.6% 9-Month Average TPR-NH (Pre-Dose) ‘5-Month Average TPR-Phase 1b (Post-Dosa) Standard Deviation = 2.2 units ‘Standard Deviation = 2.6 units
Slide 3: Moderately Thick Liquid, Total Pharyngeal Residue %
Moderately Thick Liquid, Total Pharyngeal Residue % Pre-Dose Avg. TPR: 18.2% Lowest TPR-NH: 10.5% Post-Dose Avg. TPR: 10.0% 9 Mont erage TPR-NH re-Dase) ‘Standard Deviation = 12.3 units ‘© Month Average TPR-Prase Tb (Post Doe) ‘Standard Deviation = 1.5 units
Slide 4: Extremely Thick Liquid, Total Pharyngeal Residue %
2s 20 18 10 Extremely Thick Liquid, Total Pharyngeal Residue % Pre-Dose Avg. TPR: 21.5% Lowest TPR-NH: 15.0% ‘Month Average TPR-NH (Pre-Dose) ‘Standard Deviation = 8.6 units Post-Dose Avg. TPR: 12.0% 6-Month Average TPR-Phase 1b (Post-Dose) ‘Standard Deviation = 0.1 units
Slide 5: Figure 3—Subject-Reported SSQ Total Score for Subject 1
*Company data on file; Avg. = Average, TPR = Total Pharyngeal Residue, NH = OPMD Natural History Study Figure 3—Subject-Reported SSQ Total Score for Subject 1: Pre-Dose Average and 180-Day Post-Dose Average *
Slide 6: BB-301 Safety Profile and About OPMD
*Company data on file; Avg. = Average, SSQ = Sydney Swallow Questionnaire, NH = OPMD Natural History Study Regarding the BB-301 safety profile observed to date, transient Grade 2 Gastroesophageal Reflux Disease or “GERD” (i.e., “acid reflux” or “heartburn”) has been reported previously in April 2024